Influenza A(H1N1)pdm09: beyond the pandemic | Enfermedades Infecciosas y Microbiología Clínica

Article information

Abstract

On August 2010, the World Health Organization declared the end to the 2009 A(H1N1) pandemic. However, influenza A(H1N1)pdm09 continues to circulate as a seasonal virus. Different viruses have predominated in different parts of the world. To date, influenza A(H1N1)pdm09 has demonstrated little antigenic drift, and its oseltamivir resistance has remained low. In some countries, a higher number of severe cases of influenza A(H1N1)pdm09 infection were documented during the 2010–2011 season than during the pandemic period. In addition, delays in oseltamivir administration, higher ages and comorbidities and low vaccination rates in patients with influenza A(H1N1)pdm09 infection were found during the first postpandemic season. Therefore, physicians should carefully consider the pandemic virus as a possible causative agent in patients with influenza-like illnesses admitted to emergency departments. In addition, surveillance systems and vaccination campaigns should continue after the pandemic period.

Keywords:

Influenza A(H1N1)pdm09

Post-pandemic period

Oseltamivir

Clinical features

Prognosis

Resumen

En agosto de 2010, la Organización Mundial de la Salud declaró el fin de la pandemia de la gripe H1N1. Sin embargo, el virus de la gripe A(H1N1)pdm09 continúa circulando como un virus estacional. Significativamente, diferentes virus han predominado en diferentes partes del mundo en el período pospandémico. Hasta la fecha, el virus de la gripe A(H1N1)pdm09 ha demostrado pocos cambios antigénicos, y la resistencia a oseltamivir se ha mantenido baja. En algunos países se ha documentado un mayor número de casos graves debidos al virus de la gripe A (H1N1)pdm09 durante la temporada de gripe 2010–2011. Además, también se ha reportado durante el primer período de gripe pospandémico: retraso en la administración de tratamiento antiviral, aumento en la edad y la frecuencia de comorbilidades, y tasas bajas de vacunación en los pacientes con infección por gripe A(H1N1)pdm09. Por lo tanto, se debe considerar el virus pandémico como un posible agente causal en pacientes con enfermedad gripal que asisten a los departamentos de emergencia. Además, los sistemas de vigilancia y campañas de vacunación deben continuar después del período pandémico.

Palabras clave:

Virus de la gripe A(H1N1)pdm09

Período pospandémico

Oseltamivir

Características clínicas

Pronóstico

Full text is only aviable in PDF

References

[1.]

J.M. Barry, C. Viboud, L. Simonsen.

Cross-protection between successive waves of the 1918–1919 influenza pandemic: epidemiological evidence from US Army camps and from Britain.

J Infect Dis, 198 (2008), pp. 1427-1434

[2.]

J.K. Taubenberger, D.M. Morens.

1918 Influenza: the mother of all pandemics.

Emerg Infect Dis, 12 (2006), pp. 15-22

http://dx.doi.org/10.3201/eid1201.050979 | Medline

[3.]

World Health Organization. H1N1 in post-pandemic period. Available at: http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/index.html.

[4.]

M. Nelson, D. Spiro, D. Wentworth, E. Beck, J. Fan, E. Ghedin, et al.

The early diversification of influenza A/H1N1pdm.

PLoS Curr, 1 (2009), pp. RRN1126

[5.]

M.I. Nelson, Y. Tan, E. Ghedin, D.E. Wentworth, K. St George, L. Edelman, et al.

Phylogeography of the spring and fall waves of the H1N1/09 pandemic influenza virus in the United States.

J Virol, 85 (2011), pp. 828-834

http://dx.doi.org/10.1128/JVI.01762-10 | Medline

[6.]

European Centre For Disease Prevention and Control (ECDC). Influenza Virus Characterization. Summary Europe, February 2012. 2012. Available at: http://ecdc.europa.eu/en/publications/Publications/1203_TED_CNRL_report_Feb2011.pdf.

[7.]

J. Ledesma, F. Pozo, G. Reina, M. Blasco, G. Rodríguez, M. Montes, et al.

Spanish Influenza Surveillance System (SISS). Genetic diversity of influenza A(H1N1)2009 virus circulating during the season 2010–2011 in Spain.

J Clin Virol, 53 (2012), pp. 16-21

http://dx.doi.org/10.1016/j.jcv.2011.09.032 | Medline

[8.]

Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season.

Wkly Epidemiol Rec, 8710 (2012), pp. 83-95

[9.]

G. Neumann, T. Noda, Y. Kawaoka.

Emergence and pandemic potential of swineorigin H1N1 influenza virus.

Nature, 459 (2009), pp. 931-939

http://dx.doi.org/10.1038/nature08157 | Medline

[10.]

R.J. Garten, C.T. Davis, C.A. Russell, B. Shu, S. Lindstrom, A. Balish, et al.

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.

Science, 325 (2009), pp. 197-201

http://dx.doi.org/10.1126/science.1176225 | Medline

[11.]

A. Antón, M.A. Marcos, M.J. Martínez, S. Ramón, A. Martínez, N. Cardeñosa, et al.

D225G mutation in the hemagglutinin protein found in 3 severe cases of 2009 pandemic influenza A (H1N1) in Spain.

Diagn Microbiol Infect Dis, 67 (2010), pp. 207-208

http://dx.doi.org/10.1016/j.diagmicrobio.2010.02.002 | Medline

[12.]

A. Kilander, R. Rykkvin, S.G. Dudman, O. Hungnes.

Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome. Norway 2009–2010.

Euro Surveill, 15 (2010), pp. 19498

[13.]

J. Ledesma, F. Pozo, M.P. Ruiz, J.M. Navarro, L. Piñeiro, M. Montes, et al.

Spanish Influenza Surveillance System (SISS). Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain.

J Clin Virol, 51 (2011), pp. 75-78

http://dx.doi.org/10.1016/j.jcv.2011.01.020 | Medline

[14.]

J. Stevens, O. Blixt, L. Glaser, J.K. Taubenberger, P. Palese, J.C. Paulson, et al.

Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities.

J Mol Biol, 355 (2006), pp. 1143-1155

http://dx.doi.org/10.1016/j.jmb.2005.11.002 | Medline

[15.]

J.A. Belser, A. Jayaraman, R. Raman, C. Pappas, H. Zeng, N.J. Cox, et al.

Effect of D222G mutation in the hemagglutinin protein on receptor binding, pathogenesis and transmissibility of the 2009 pandemic H1N1 influenza virus.

PLoS One, 6 (2011), pp. e25091

http://dx.doi.org/10.1371/journal.pone.0025091 | Medline

[16.]

S. Kumar, K.J. Henrickson.

Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic.

Clin Microbiol Rev, 25 (2012), pp. 344-361

http://dx.doi.org/10.1128/CMR.05016-11 | Medline

[17.]

Centers for Disease and Control and Prevention (CDC).

Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.

MMWR Morb Mortal Wkly Rep, 58 (2009), pp. 433-435

Medline

[18.]

WHO Global Influenza Surveillance and Response System (GISRS). Summary of influenza antiviral susceptibility surveillance findings, September 2010 - March 2011. Available at: http://www.who.int/influenza/gisrs_laboratory/updates/antiviral_susceptibility/en/index.html.

[19.]

World Health Organization. Influenza Update N° 160. 2012. Available at: http://www.who.int/influenza/surveillance_monitoring/updates/2012_05_25_surveilance_update_160.pdf.

[20.]

A.C. Hurt, T. Chotpitayasunondh, N.J. Cox, R. Daniels, A.M. Fry, L.V. Gubareva, et al.

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.

Lancet Infect Dis, 12 (2012), pp. 240-248

http://dx.doi.org/10.1016/S1473-3099(11)70318-8 | Medline

[21.]

H.T. Nguyen, A.M. Fry, L.V. Gubareva.

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Antivir Ther, 17 (2012), pp. 159-173

http://dx.doi.org/10.3851/IMP2067 | Medline

[22.]

A. Anton, T. Pumarola.

Influenza in immunocompromised patients: considerations for therapy.

Future Virology, 6 (2011), pp. 855-868

[23.]

World Health Organization.

Review of the 2010–2011 winter influenza season, northern hemisphere.

Wkly Epidemiol Rec, 86 (2011), pp. 222-227

Medline

[24.]

S. Bolotin, R. Pebody, P.J. White, J. McMenamin, L. Perera, J.S. Nguyen-Van-Tam, et al.

UK Severe Influenza Surveillance System (USISS) Steering Group. A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period.

PLoS One, 7 (2012), pp. e30279

http://dx.doi.org/10.1371/journal.pone.0030279 | Medline

[25.]

M. Athanasiou, A. Baka, A. Andreopoulou, G. Spala, K. Karageorgou, L. Kostopoulos, et al.

Influenza surveillance during the post-pandemic influenza 2010/11 season in Greece, 04 October 2010 to 22 May 2011.

Euro Surveill, 16 (2011), pp. 20004

[26.]

Vigilancia de la gripe en España. Temporada 2010–2011. Área de Vigilancia de la Salud Pública. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Available at: http://vgripe.isciii.es/gripe/documentos/20102011/InformesAnuales/Informe_GRIPE_Temporada_2010-11_07092011.pdf.

[27.]

J.H. Chuang, A.S. Huang, W.T. Huang, M.T. Liu, J.H. Chou, F.Y. Chang, et al.

Nationwide Surveillance of Influenza during the Pandemic (2009–10) and Post-Pandemic (2010–11) Periods in Taiwan.

PLoS One, 7 (2012), pp. e36120

http://dx.doi.org/10.1371/journal.pone.0036120 | Medline

[28.]

World Health Organization. Influenza Update N° 159. Available at: http://www.who.int/influenza/surveillance_monitoring/updates/2012_05_10_surveilance_update_159.pdf.

[29.]

Public Health Agency of Canada. FluWatch. Available at: http://www.phac-aspc.gc.ca/fluwatch/11-12/w19_12/pdf/fw2012-19-eng.pdf.

[30.]

Área de Vigilancia de la Salud Pública. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Informe semanal de Vigilancia de la Gripe en España. Available at: http://vgripe.isciii.es/gripe/documentos/20112012/boletines/grn2012.pdf.

[31.]

D. Viasus, E. Cordero, J. Rodríguez-Baño, J.A. Oteo, A. Fernández-Navarro, L. Ortega, et al.

Novel Influenza A (H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season.

Clin Microbiol Infect, 18 (2012), pp. E55-E62

[32.]

I. Martin-Loeches, E. Díaz, L. Vidaur, A. Torres, C. Laborda, R. Granada, H1N1 SEMICYUC/REIPI/CIBERES Working group, et al.

Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients.

Crit Care, 15 (2011), pp. R286

[33.]

D. Viasus, J.R. Paño-Pardo, J. Pachón, M. Riera, F. López-Medrano, A. Payeras, et al.

Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.

Chest, 140 (2011), pp. 1025-1032

http://dx.doi.org/10.1378/chest.10-2792 | Medline